Details of the Drug

General Information of Drug (ID: DMJ5MPG)

Drug Name
BDC-1001
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Drug Type
Antibody drug conjugate
Cross-matching ID
TTD ID
D1XI9E

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carcinoembryonic antigen CEA (CD66e) TTY6DTE CEAM5_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 6.68E-91 0.29 1.07
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04278144) A First-in-human Study Using BDC-1001 in Advanced HER2-Expressing Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Bolt Biotherapeutics.